GNLX
GENELUX Corp
GENELUX Corp (GNLX) has 16 SEC Form 4 filings (16 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jul 2, 2026.
- Industry:Biotechnology
- CEO:Thomas D. Zindrick
- Employees:24
- HQ:Westlake Village, CA, US
- IPO:2023-01-26
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$78K
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Market Cap
$132.7M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Smither John WFirst filing | Director | Sale | 12,000 | $35K | Jul 2 | SEC ↗ |
| Head of Regulatory | Sale | 192 | $563 | Jun 5 | SEC ↗ | |
Thomas JohnFirst filing | Director | Sale | 10,000 | $30K | Jun 3 | SEC ↗ |
Yu YongFirst filing | Chief Scientific Officer | Sale | 605 | $2K | May 13 | SEC ↗ |
Cappello JosephFirst filing | Chief Technical Officer | Sale | 605 | $2K | May 13 | SEC ↗ |
Zindrick ThomasFirst filing | President and CEO | Sale | 2,798 | $8K | May 13 | SEC ↗ |
Smalling RalphFirst filing | Head of Regulatory | Sale | 270 | $804 | May 13 | SEC ↗ |
Related companies
GENELUX Corp is in the Healthcare sector.